Download PDF
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0045-1809622
Case Report

Excellent Objective Response to Lenvatinib in a Patient of Recurrent Radioiodine Refractory Poorly Differentiated Thyroid Carcinoma

Mali Madhava Reddy 
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Priyanka Verma 
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sandip Basu 
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
  Permissions and Reprints

Abstract

We herein present a patient of recurrent radioiodine refractory poorly differentiated thyroid carcinoma (PDTC) with excellent response to lenvatinib in recurrent setting. The patient was a known case of PDTC, operated for primary followed by local radiotherapy to the neck. The patient presented with recurrence at 8 years' follow-up with left-sided supraclavicular neck swelling and elevated serum thyroglobulin levels. Biopsy from the supraclavicular nodal mass demonstrated metastasis in known case of PDTC. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) done for disease extent evaluation, demonstrated two hypermetabolic large volume soft tissue density nodal masses in the left supraclavicular region and anterior mediastinum. The patient was administered lenvatinib with possible surgical intent as the disease was unresectable due to encasement of critical vessels (left common carotid artery). Four months into the therapy with lenvatinib, response evaluation 18F-FDG PET/CT showed excellent partial response, which lasted for a year, and the disease eventually progressed.

Keywords

[18F]FDG-PET/CT - lenvatinib - objective response - poorly differentiated thyroid carcinoma - radioiodine refractory


Publication History

Article published online:
09 June 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ibrahimpasic T, Ghossein R, Shah JP, Ganly I. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 2019; 29 (03) 311-321
    PubMedSearch in Google Scholar
  • 2 DeLellis RA, Lloyd RV, Heinz PU, Eng C. Pathology and genetics of tumours of endocrine organs. In: WHO Classification of Tumours. 3rd ed. Lyon: IARC Press; 2004
    Search in Google Scholar
  • 3 Filetti S, Durante C, Hartl D. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30 (12) 1856-1883
    CrossrefPubMedSearch in Google Scholar
  • 4 Puliafito I, Esposito F, Prestifilippo A. et al. Target therapy in thyroid cancer: current challenge in clinical use of tyrosine kinase inhibitors and management of side effects. Front Endocrinol (Lausanne) 2022; 13: 860671
    PubMedSearch in Google Scholar
  • 5 Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016; 42: 47-55
    CrossrefPubMedSearch in Google Scholar
  • 6 Schlumberger M, Tahara M, Wirth LJ. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372 (07) 621-630
    CrossrefPubMedSearch in Google Scholar
  • 7 Brose MS, Panaseykin Y, Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 2022; 107 (03) 776-787
    PubMedSearch in Google Scholar
  • 8 Rendl G, Schweighofer-Zwink G, Sorko S. et al. Assessment of treatment response to lenvatinib in thyroid cancer monitored by F-18 FDG PET/CT using PERCIST 1.0, modified PERCIST and EORTC criteria-which one is most suitable?. Cancers (Basel) 2022; 14 (08) 1868
    PubMedSearch in Google Scholar
  • 9 Wirth LJ, Durante C, Topliss DJ. et al. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit. Oncologist 2022; 27 (07) 565-572
    PubMedSearch in Google Scholar
  • 10 Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018; 25 (06) 699-704
    CrossrefPubMedSearch in Google Scholar
  • 11 Roque J, Nunes Silva T, Regala C, Rodrigues R, Leite V. Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma. Eur Thyroid J 2023; 12 (02) e230003
    PubMedSearch in Google Scholar
  • 12 Bo W, Chen Y. Lenvatinib resistance mechanism and potential ways to conquer. Front Pharmacol 2023; 14: 1153991
    PubMedSearch in Google Scholar
  • 13 Gay S, Monti E, Trambaiolo Antonelli C. et al. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncol 2019; 15 (24s): 13-19
    PubMedSearch in Google Scholar
  • 14 Katoh H, Kajita S, Yokota M, Sengoku N, Sangai T. Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels. Int J Endocr Oncol 2020; 7: 3
    Search in Google Scholar
  • 15 Yu J, Wu Y. 2227P The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: a single-arm phase II clinical trial. Ann Oncol 2023; 34: S1147
    Search in Google Scholar
  • 16 Tsuboi M, Takizawa H, Aoyama M, Tangoku A. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int J Surg Case Rep 2017; 41: 89-92
    PubMedSearch in Google Scholar
  • 17 Brose MS, Robinson BG, Sherman SI. et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 2022; 128 (24) 4203-4212
    PubMedSearch in Google Scholar